Quick Answer
TG THERAPEUTICS, INC. reported Total Revenue of $616.29 million for fiscal year 2025.
TG THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $616.29M +87.3% |
$329.00M +40.8% |
$233.66M +8290.0% |
$2.79M -58.4% |
$6.69M +4300.7% |
$152.0K +0.0% |
| Revenue (ASC 606) | $616.29M +87.3% |
$329.00M +40.8% |
$233.66M +8290.0% |
$2.79M -58.4% |
$6.69M | — |
| Net Income | $447.18M +1812.4% |
$23.38M +84.5% |
$12.67M +105.7% |
-$223.81M +35.7% |
-$348.10M | — |
| Diluted EPS | $2.77 +1746.7% |
$0.15 +66.7% |
$0.09 +105.5% |
-$1.65 +37.3% |
-$2.63 -8.7% |
-$2.42 |
| Total Assets | $1.06B +84.1% |
$577.69M +75.3% |
$329.59M +70.3% |
$193.57M -49.0% |
$379.63M -39.3% |
$625.64M +283.8% |
| Cash and Equivalents | $79.15M -56.0% |
$179.89M +93.6% |
$92.93M -9.2% |
$102.30M -65.8% |
$298.89M -46.0% |
$553.44M +391.3% |
| Long-Term Debt | $245.65M +0.5% |
$244.43M +144.1% |
$100.12M +40.7% |
$71.14M +6.5% |
$66.79M +765.6% |
$7.72M -73.4% |
| Stockholders Equity | $648.02M +191.4% |
$222.36M +38.5% |
$160.50M +174.0% |
$58.59M -75.3% |
$237.15M -54.3% |
$519.35M +1244.9% |
| R&D Expense | $160.22M +69.9% |
$94.29M +23.8% |
$76.19M -39.2% |
$125.35M -43.7% |
$222.58M +34.2% |
$165.90M +7.6% |
| Operating Income | $123.32M +194.1% |
$41.93M +103.2% |
$20.63M +109.5% |
-$218.32M +36.7% |
-$344.77M -26.0% |
-$273.59M -61.8% |
| Shares Outstanding | 155.31M -0.3% |
155.84M +2.9% |
151.42M +3.4% |
146.39M +2.2% |
143.25M +1.9% |
140.58M +28.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $161.71M | +92.8% | +14.6% |
| Revenue (ASC 606) | September 30, 2025 | $161.71M | +92.8% | +14.6% |
| Net Income | September 30, 2025 | $390.89M | +9974.6% | +1286.8% |
| Diluted EPS | September 30, 2025 | $2.43 | +12050.0% | +1329.4% |
| Total Assets | September 30, 2025 | $1.03B | +74.9% | +45.9% |
| Cash and Equivalents | September 30, 2025 | $74.08M | -62.2% | -42.6% |
| Long-Term Debt | September 30, 2025 | $245.34M | +0.5% | +0.1% |
| Stockholders Equity | September 30, 2025 | $607.22M | +216.0% | +119.7% |
| R&D Expense | September 30, 2025 | $40.88M | +103.0% | +28.6% |
| Operating Income | September 30, 2025 | $29.36M | +136.2% | -15.7% |
| Shares Outstanding | September 30, 2025 | 155.21M | -0.4% | -1.8% |
- TG THERAPEUTICS, INC. reported Total Revenue of $616.29 million for fiscal year 2025.
- TG THERAPEUTICS, INC. showed an increase of +87.3% in Total Revenue compared to the prior fiscal year.
- TG THERAPEUTICS, INC. reported Revenue (ASC 606) of $616.29 million for fiscal year 2025.
- TG THERAPEUTICS, INC. showed an increase of +87.3% in Revenue (ASC 606) compared to the prior fiscal year.
- TG THERAPEUTICS, INC. reported Net Income of $447.18 million for fiscal year 2025.
- TG THERAPEUTICS, INC. showed an increase of +1812.4% in Net Income compared to the prior fiscal year.
- TG THERAPEUTICS, INC. reported Diluted EPS of $2.77 per share for fiscal year 2025.
- TG THERAPEUTICS, INC. showed an increase of +1746.7% in Diluted EPS compared to the prior fiscal year.
- TG THERAPEUTICS, INC. reported Total Assets of $1.06 billion for fiscal year 2025.
- TG THERAPEUTICS, INC. showed an increase of +84.1% in Total Assets compared to the prior fiscal year.
- TG THERAPEUTICS, INC. reported Cash and Equivalents of $79.15 million for fiscal year 2025.
- TG THERAPEUTICS, INC. showed a decrease of -56.0% in Cash and Equivalents compared to the prior fiscal year.
- TG THERAPEUTICS, INC. reported Long-Term Debt of $245.65 million for fiscal year 2025.
- TG THERAPEUTICS, INC. showed an increase of +0.5% in Long-Term Debt compared to the prior fiscal year.
- TG THERAPEUTICS, INC. reported Stockholders Equity of $648.02 million for fiscal year 2025.
- TG THERAPEUTICS, INC. showed an increase of +191.4% in Stockholders Equity compared to the prior fiscal year.
- TG THERAPEUTICS, INC. reported R&D Expense of $160.22 million for fiscal year 2025.
- TG THERAPEUTICS, INC. showed an increase of +69.9% in R&D Expense compared to the prior fiscal year.
- TG THERAPEUTICS, INC. reported Operating Income of $123.32 million for fiscal year 2025.
- TG THERAPEUTICS, INC. showed an increase of +194.1% in Operating Income compared to the prior fiscal year.
- TG THERAPEUTICS, INC. reported Shares Outstanding of 155.31 million shares for fiscal year 2025.
- TG THERAPEUTICS, INC. showed a decrease of -0.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: